
Today’s Yangtze funding roundup: Biopharma, physical AI infra…
Biotech and physical AI startups raised fresh capital to advance clinical programs and next-generation robotics infrastructure.

Biotech and physical AI startups raised fresh capital to advance clinical programs and next-generation robotics infrastructure.

The “Solar Valley” will comprise three zones covering scientific research, industrial support and startup incubation.

The company delivered about 30,000 units globally in 2025, with products sold across more than 70 countries and regions.

The company aims to move 3D content creation from labor-intensive manual modeling toward automated, large-scale production.

As companies move toward commercialization, major competitions can serve as public demonstrations of technical capability.

That makes the program resemble an early-stage technology grant or angel investment more than a conventional corporate recruitment scheme.

Embodied AI and chip startups drew fresh capital as China accelerates investment in next-generation computing infrastructure.

For international investors, the plan offers a relatively clear picture of where Shanghai expects its next wave of industrial growth to come from.

Once completed, China Fusion Engineering Test Reactor IV is expected to compete with projects such as the US-based SPARC and the UK’s STEP.

The international launch comes as AI agents move beyond chatbots toward software that can independently execute multi-step tasks.